<DOC>
	<DOCNO>NCT00227721</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , gemcitabine docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give gemcitabine together docetaxel work treat patient relapsed refractory ovarian epithelial peritoneal cancer .</brief_summary>
	<brief_title>Gemcitabine Docetaxel Treating Patients With Relapsed Refractory Ovarian Epithelial Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate patient platinum-sensitive -resistant relapse refractory ovarian epithelial peritoneal cavity cancer treat gemcitabine docetaxel . Secondary - Determine toxicity regimen patient . - Determine overall survival patient treat regimen . - Determine time treatment failure progression-free survival patient treat regimen . OUTLINE : This multicenter study . Patients stratify accord response prior treatment platinum-containing regimen ( platinum-resistant disease v platinum-sensitive disease ) . Patients receive gemcitabine IV 30 minute docetaxel IV 30 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) receive 3 additional course beyond CR ( ≥ 6 total course treatment ) . PROJECTED ACCRUAL : Approximately 36-62 patient ( 19-29 stratum I [ platinum-resistant disease ] 17-33 stratum II [ platinum-sensitive disease ] ) accrue study .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial peritoneal cavity cancer Relapsed refractory disease prior firstline therapy platinumcontaining regimen Platinumsensitive resistant disease Platinum resistance define relapsed progressive disease within 6 month completion platinumcontaining regimen Measurable evaluable disease Evaluable disease define CA 125 &gt; 70 U/mL double baseline determination confirm ≥ 2 separate blood sample take &gt; 4 week apart OR evidence demonstrate progressive disease initial treatment regimen PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 8.0 g/dL Hepatic Bilirubin normal Meets 1 follow criterion : AST ALT normal AND alkaline phosphatase ( AP ) ≤ 5 time upper limit normal ( ULN ) AST ALT ≤ 1.5 time ULN AND AP ≤ 2.5 time ULN AST ALT ≤ 5 time ULN AND AP normal Renal Creatinine clearance &gt; 30 mL/min Creatinine &lt; 2.5 mg/dL Cardiovascular No congestive heart failure No second third degree heart block No myocardial infarction within past 3 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No peripheral neuropathy &gt; grade 1 No malignancy within past 2 year except adequately treated skin cancer carcinoma situ cervix No history severe hypersensitivity reaction drug formulate polysorbate 80 PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Prior paclitaxel allow No 1 prior chemotherapy regimen Firstline platinumbased chemotherapy follow consolidation therapy set clinical serologic complete response consider 1 regimen No prior gemcitabine docetaxel Endocrine therapy Not specify Radiotherapy At least 4 week since prior radiotherapy recover Surgery Not specify Other More 28 day since prior concurrent investigational drug cancer No concurrent treatment alternative therapy cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>